

**How to cite this article:**

- García-Robles AA, López Briz E, Fraga Fuentes MD, Asensi Díez R,
- Sierra Sánchez JF. Review of oritavancin for the treatment of acute
- bacterial skin and skin structure infections. *Farm Hosp.* 2018;42(2):73-81.



## REVIEWS

Bilingual edition english/spanish

## Review of oritavancin for the treatment of acute bacterial skin and skin structure infections

### Revisión crítica de la oritavancina en infecciones de la piel y tejidos blandos

Ana Alejandra García-Robles<sup>1</sup>, Eduardo López Briz<sup>1</sup>, María Dolores Fraga Fuentes<sup>2</sup>, Rocío Asensi Díez<sup>3</sup>, Jesús Francisco Sierra Sánchez<sup>4</sup>

<sup>1</sup>Servicio de Farmacia, Hospital Universitario y Politécnico La Fe, Valencia. Spain. <sup>2</sup>Servicio de Farmacia, Hospital La Mancha Centro, Alcázar de San Juan, Ciudad Real. Spain. <sup>3</sup>Servicio de Farmacia, Hospital Regional Universitario Carlos Haya, Málaga. Spain. <sup>4</sup>Servicio de Farmacia, UGC Farmacia, AGS Norte de Cádiz, Cádiz. Spain.

<sup>\*</sup>Este artículo es un resumen del informe de evaluación de la oritavancina realizado por GENESIS-SEFH (Grupo de Evaluación de Novedades, Estandarización e Investigación en Selección de Medicamentos de la Sociedad Española de Farmacia Hospitalaria), que puede obtenerse de forma completa desde la página web de GENESIS (<http://gruposedetrabajo.sefh.es/genesis/>). Esta evaluación se ha realizado con la ayuda de la aplicación MADRE 4.0<sup>\*</sup>.

**Author of correspondence**

Ana Alejandra García-Robles  
Avda. Fernando Abril Martorell, 106.  
46026 Valencia. España.

Correo electrónico:  
garcia\_anarob@gva.es

• Recibido el 12 de abril de 2017;  
• aceptado el 28 de agosto de 2017.

• DOI: 10.7399/fh.10807

**Abstract**

**Objective:** To assess critically oritavancin, a second-generation lipoglycopeptide, for the treatment of Acute Bacterial Skin and Skin Structure Infections caused by susceptible Gram-positive bacteria, including methicillin-resistant *Staphylococcus aureus*.

**Method:** An evaluation report of oritavancin in Acute Bacterial Skin and Skin Structure Infections was carried out according to the methodology of the Group for drug evaluation, standardization and research in drug selection of the Spanish Society of Hospital Pharmacy (SEFH)<sup>1</sup>, with the MADRE 4.0 program. A search was made in PubMed, in the web [www.clinicaltrials.gov](http://www.clinicaltrials.gov), Embase, PubMed and UptoDate. The European Medication Agency and Food and Drug Administration evaluation reports were also used.

**Results:** Single-dose oritavancin demonstrated its non-inferiority efficacy versus vancomycin in Acute Bacterial Skin and Skin Structure Infections, with a similar safety profile. Its potential advantage over other therapeutic alternatives lies in its administration in single dose and in its no need for plasma levels monitoring, which would allow its administration on an outpatient basis. Regarding to the other alternative possibilities of oral (linezolid, tedizolid) or IM (teicoplanin) treatment, oritavancin would improve the adherence to the treatment.

Although oritavancin could be more efficient in certain scenarios (outpatient treatment versus inpatient treatment with alternatives), there are no convincing studies in this regard so far. On the other hand, alternative drugs above-mentioned, can also allow outpatient treatment, reducing advantages of oritavancin and further increasing cost differences. Therefore, given that the efficacy is similar to the alternatives, a cost minimization analysis could be considered.

**Resumen**

**Objetivo:** Evaluar críticamente la oritavancina, lipoglicopéptido de segunda generación, para el tratamiento de la infección bacteriana aguda de la piel y tejidos blandos causada por bacterias Gram-positivas susceptibles, incluyendo *Staphylococcus aureus* resistente a metilina.

**Método:** Se realizó un informe de evaluación según la metodología del Grupo de Evaluación de Novedades, Estandarización e Investigación en Selección de Medicamentos de la Sociedad Española de Farmacia Hospitalaria, con el programa MADRE 4.0. Se llevó a cabo una búsqueda en PubMed, en [www.clinicaltrials.gov](http://www.clinicaltrials.gov), Embase y UptoDate. También se utilizaron informes publicados de agencias de evaluación.

**Resultados:** La oritavancina en dosis única demostró no ser inferior a la vancomicina en Infección bacteriana aguda de la piel y tejidos blandos, con un perfil de seguridad similar. Sus ventajas potenciales frente a otras alternativas terapéuticas radicarían en su administración en dosis única y en la no necesidad de monitorización de los niveles plasmáticos (lo que posibilitaría su administración ambulatoria), y en la mejora de la adherencia. Aunque podría ser eficiente en determinados escenarios (tratamiento ambulatorio frente al hospitalario con las alternativas), no hay estudios convincentes en este sentido. Por otra parte, los fármacos alternativos por vía oral (linezolid, tedizolid) o IM (teicoplanina) pueden permitir también el tratamiento ambulatorio, reduciendo las ventajas de la oritavancina y agrandando las diferencias de coste. Dado que su eficacia es similar a las alternativas, cabría considerar un análisis de minimización de costes.

**KEY WORDS**

Oritavancin; Bacterial skin diseases; Glycopeptides; Acute bacterial skin and skin structure infections; Resistance; Adherence.

**PALABRAS CLAVE**

Oritavancina; Infecciones cutáneas; Glicopéptidos; Infecciones de piel y tejidos blandos; Resistencia; Adherencia.



Los artículos publicados en esta revista se distribuyen con la licencia  
Articles published in this journal are licensed with a  
Creative Commons Attribution 4.0  
<https://creativecommons.org/licenses/by-nc-nd/4.0/>  
La revista Farmacia no cobra tasas por el envío de trabajos,  
ni tampoco por la publicación de sus artículos.

**Conclusions:** Oritavancin is comparable in terms of efficacy and safety to the existing alternatives in Acute Bacterial Skin and Skin Structure Infections, without improvements in the cost-effectiveness ratio, because of the proposed positioning is to consider it for the treatment of vancomycin-resistant enterococcal infection in adult patients when the use of linezolid or tedizolid is contraindicated.

## Introduction

The current concept of acute bacterial skin and soft tissue infections (SSTIs) includes, according to the *Food and Drug Administration* (FDA)<sup>1</sup> all those infections with a minimum lesion surface area of approximately 75 cm<sup>2</sup> which are included in one of the following categories: cellulitis/erysipelas, wound infection, and major cutaneous abscess. The European Medication Agency (EMA)<sup>2,3</sup> also recommends, for the assessment of infection severity, the presence of signs or symptoms associated with an acute course of the infectious process.

Given the variable presentation of SSTIs and the frequency of recurrent episodes, it is complicated to estimate their incidence and prevalence. Different studies have been conducted in U.S.A. which show an increase during the past years<sup>4-6</sup>. In Spain, SSTIs share with gastrointestinal infections the fourth position within infections; while in a selected population, such as the elderly, they might even be the second cause of infection. According to series, SSTIs represent between 0.66% and 2.5% of the total infections<sup>7</sup>.

SSTI treatment requires a multidisciplinary approach which includes antibiotic treatment, and surgery in those cases necessary. Antimicrobial treatment, very heterogeneous and usually empirical<sup>8,9</sup>, will be conditioned by the microorganisms that colonize the skin in the affected area, the place where the infection has been acquired (hospital or community), its clinical presentation, risk factors, previous administration of antibiotics, and the local epidemiology of resistance to antimicrobial agents<sup>10</sup>.

Although there is no overall consensus about the empirical therapy for this type of infection, it seems to be acknowledged that beta-lactams are one of the most adequate treatments, in those cases where there is no suspected involvement by methicillin-resistant *Staphylococcus aureus* (MRSA)<sup>11,12</sup>. When it is suspected that the infection can be caused by MRSA, or there is evidence of this, the recommendation is to use any of the antimicrobial agents that have activity against this microorganism. There are publications highlighting the high rate of failures in first-line antibiotic therapies<sup>13</sup>.

Glycopeptides, such as vancomycin and teicoplanin, have been until recently the basis for the treatment of severe MRSA infections. However, the concern about the efficacy and gradual development of resistance (MRSA strains reach 22.1% in our country, above the European mean of 17.4%<sup>14</sup>) has led to focusing on the development of new active agents against Gram-positive bacteria. The agents approved for SSTI treatment are: linezolid, tedizolid, daptomycin and tigecycline.

Oritavancin has not been authorized by the Spanish Agency of Medicines and Medical Devices (AEMPS) at the time of preparing this report; but it has been approved by the EMA<sup>15</sup> and by the FDA<sup>16</sup> for the treatment of SSTIs in adults. Its mechanism of action is triple: on one hand, it causes the inhibition of the transglycosylation and transpeptidation stage of cell wall biosynthesis, and also causes a rupture in the integrity of the bacterial membrane<sup>17,18</sup>. This turns it active against organisms sensitive and resistant to vancomycin, as well as having a fast bactericidal activity, concentration-dependent, against Gram-positive bacteria in active growth, stationary stage, and during biofilm formation<sup>18</sup>.

The GENESIS Group (Group for drug evaluation, standardization and research in drug selection) of the Spanish Society of Hospital Pharmacy (SEFH), has a program called MADRE, available for the preparation of reports on medication evaluation that must be submitted to the Pharmacy Committees in order to make decisions about the positioning of medications in treatment and their selection for the therapeutic approach of patients.

This MADRE program contains sections about the basic cornerstones recommended to make these decisions about medication positioning: efficacy, safety and efficiency. This last section includes costs, economic evaluation, and budgetary impact.

The objective of this paper is, therefore, a critical evaluation of oritavancin according to the methodology of this work group.

**Conclusiones:** La oritavancina es de una eficacia y seguridad comparables a las alternativas existentes en Infección bacteriana aguda de la piel y tejidos blandos y no mejora la relación coste-efectividad, por lo que el posicionamiento propuesto sería el tratamiento de la infección por enterococo resistente a vancomicina en pacientes adultos cuando esté contraindicado el uso de linezolid o tedizolid.

## Methods

An exhaustive review of oritavancin in SSTI was conducted according to the MADRE 4.0 program of the GENESIS Group (Group for drug evaluation, standardization and research in drug selection) of the Spanish Society of Hospital Pharmacy (SEFH)<sup>19</sup>.

According to this program, a search was conducted for efficacy and safety in the Clinical Queries tool of PubMed, with the following words: "oritavancin AND phase III" in the "narrow" field, and another search with "oritavancin AND trial", in the "narrow" field. A search was conducted in the www.clinicaltrials.gov website with the word "oritavancin".

The EPAR Report by the EMA (2015) and the CDER Report by the FDA (2014) were also used. In these, there is a description of 2 pivotal clinical trials on Phase III and a Phase II clinical trial (the CDER Report also mentions 2 pivotal clinical trials on Phase III that were described in the 2008 CDER Report).

A search was also conducted in PubMed and Embase with the descriptor "oritavancin", which was limited to "systematic reviews" OR "meta-analysis".

For the economic evaluation, a search was conducted in PubMed and Embase with the descriptors "oritavancin" and "economic". Data were analyzed according to the guidelines<sup>20</sup>.

## Results

On 16/12/15 there was a search in the Clinical Queries tool of PubMed, with the following words: "oritavancin AND phase III" in the "narrow" field, without any results. On 16/12/15, there was a search in the Clinical Queries tool of PubMed, with the following words: "oritavancin AND trial" in the "narrow" field, achieving 5 results: 4 clinical trials (2 Phase III, 1 Phase II, and 1 Phase I), and an opinion article.

On 15/12/15 there was a search in the www.clinicaltrials.gov website with the words "oritavancin", and 10 clinical trials were retrieved in adults (two in Phase III known as TMC-ORI-10-01 and TMC-ORI-10-02, one in Phase II called TAR-ORI-SD001, and seven in Phase I), as well as a clinical trial on paediatric population in the recruitment stage (Phase I).

There are four published pivotal clinical trials, and another clinical trial of interest. Out of the clinical trials found, two compared the drug evaluated vs. vancomycin + cefalexin, two with vancomycin, and one with oritavancin at different doses and frequencies.

There was also a search in PubMed and Embase with the descriptor "oritavancin", which was limited to "systematic reviews" OR "meta-analysis". Respectively, seven and 21 results were obtained, and after eliminating duplicates and articles that did not meet the criteria required, these were limited to one single network meta-analysis.

For economic evaluation, a search was conducted in PubMed and Embase with the descriptors "oritavancin" and "economic". Four articles were retrieved.

### 1. Efficacy

Three clinical trials have been analyzed in order to conduct the evaluation. Other articles have not been taken into account because they had been evaluated in a previous application for marketing (which the company decided to withdraw when the conclusion by the Committee for Medicinal Products for Human Use of the EMA was that there was not enough evidence for its use), because they had used patient populations with a less strict diagnosis of STTI, or because they used doses and frequencies different from those currently studied.

In the EPAR Report by the EMA<sup>15</sup> (2015) and the CDER<sup>16</sup> Report by the FDA (2014), three clinical trials are mentioned:

- SIMPLIFI (TAR-ORI-SD001)<sup>21</sup>: A Phase II, multicenter, randomized, double-blind, non-inferiority, parallel clinical trial, with active comparator, on patients with complicated skin and soft tissue infection, assumed

or confirmed to be caused by Gram-positive pathogens. In total, 311 patients were included, and 302 of them received the study medication: 100 patients in the arm with daily dose of oritavancin (control arm), 99 in the arm with 1,200 mg single dose, and 103 in the 800 mg arm (+ 400 mg optional). This is a dose-ranging clinical trial which compared 3 different doses of oritavancin. Its outcomes appear on table 1.

- SOLO I (TMC-ORI-10-01) AND SOLO II (TMC-ORI-10-02) CLINICAL TRIALS: These are pivotal studies with the same design, on Phase III, multicenter, double-blind, non-inferiority, randomized, comparing a single-dose of IV oritavancin 1,200 mg vs. vancomycin 1g or 15 mg/kg/12h during 7-10 days. The inclusion criteria were: patients  $\geq$  18 year-old, with informed consent, diagnosed with SSTI on a minimum 75 cm<sup>2</sup> surface or knowledge that it had been caused by a Gram-positive pathogen, requiring at least 7 days of IV therapy. Some of the exclusion criteria were: previous systemic or topical treatment with agents active against Gram-positive pathogens 14 days before randomization, associated in-

fections with prosthetic devices, severe sepsis or refractory shock, known or suspected bacteremia at the time of screening, CD4 < 200 cells/ $\mu$ L in HIV patients, neutropenia with an absolute neutrophil count (ANC) < 500 cells/ $\mu$ L, contraindication for administering vancomycin, liver function tests  $\geq$  3x upper limit of normal (ULN) or total bilirubin  $\geq$  2x ULN; presence of hyperuricemia or gouty arthritis, or patients not willing to abstain from the chronic use of any medication with antipyretic properties.

The outcomes of both studies have been published by Corey *et al.* in two articles<sup>22,23</sup> and are summarized in Tables 2 and 3, respectively.

Regarding the validity of clinical trials, the risk of bias has only been analyzed in the pivotal clinical trials, SOLO I and SOLO II, because SIMPLIFI is a dose escalation and determination study.

Besides, there is an indirect comparison available that has been published, where the combined "Test-of-Cure" (cure at 1-2 weeks after completing treatment) for the population clinically assessable included 14 treatments in 20 studies. Only the SOLO I and SOLO II studies were included in order

**Table 1.** TAR-ORI-SD001 (SIMPLIFI) trial outcomes<sup>20</sup>

Variable evaluated in the study	Oritavancin 1,200 mg single-dose N= 99	Oritavancin 800 mg + 400 (if needed) N= 103	Oritavancin 200 mg/24h 7-10 days (Control arm) N= 100	Difference / ARR / HR (90% CI)	P	NNT (90% CI)
<b>ITT Population</b>	N=99	N=103	N=87			
Primary outcome - test-of-cure (cure or improvement vs. failure) in the ITT population at the first follow-up visit (at day 21-29)	72/88 (81.8%)	68/87 (78.2%)	63/87 (72.4%)	Ori 1,200 mg vs Ori 200 mg 8.7 (-1.7, 17.8)	DK	-
				Ori 800 mg vs Ori 200 mg 5.1 (-5.8, 14.6)	DK	-
<b>Population: clinically evaluable</b>	N =81	N =71	N =76			
Primary outcome - test-of-cure (cure or improvement vs. failure) in the clinically evaluable population at the first follow-up visit (at day 21-29)	66/81 (81.5%)	55/71 (77.5%)	55/76 (72.4%)	Ori 1,200 mg vs Ori 200 mg 8.6 (-2.5, 18.2)	DK	-
				Ori 800 mg vs Ori 200 mg 5.2 (-6.8, 15.4)	DK	-
<b>Population: microbiological ITT</b>	N =61	N =62	N =64			
Secondary outcome - test-of-cure (cure or improvement vs. failure) in the population with microbiological ITT at the first follow-up visit (at day 21-29)	49/61 (80.3%)	50/62 (80.6%)	44/64 (68.8%)	Ori 1,200 mg vs Ori 200 mg 10.1 (-2.7, 20.9)	DK	-
				Ori 800 mg vs Ori 200 mg 11.1 (-1.5, 21.7)	DK	-
<b>Population: microbiologically evaluable</b>	N =61	N =62	N =64			
Secondary outcome - test-of-cure (cure or improvement vs. failure) in the microbiologically evaluable population at the first follow-up visit (at day 21-29)	46/58 (79.3%)	39/48 (81.3%)	38/55 (69.1%)	Ori 1,200 mg vs Ori 200 mg 8.5 (-5.2, 20.0)	DK	-
				Ori 800 mg vs Ori 200 mg 11.0 (-2.9, 22.6)	DK	-

ITT: Intention to treat.

**Table 2.** SOLO I trial outcomes<sup>21</sup>

Variable evaluated in the study	Oritavancin N= 483	Vancomycin N= 485	Difference / ARR /HR (95% CI)	P	NNT (95% CI)
<b>Population: ITT modified</b>	N=475 (%)	N=479 (%)			
<b>Primary outcome</b> - Early clinical response at the evaluation visit (48-72h) (outcome formed by stop in the spread of infection or reduction in lesion size, lack of fever and no need for antibiotic reliever medication)	391/475 (82.3)	378/479 (78.9)	3.4 (-1.6 to 8.4)	0.184	-
<b>Secondary outcome</b> - Reduction in lesion area ≥ 20 %	413/475 (86.9)	397/479 (82.9)	4.1 (-0.5 to 8.6)	0.077	-
<b>Secondary outcome</b> - Evaluation of clinical cure by the researcher	378/475 (79.6)	383/479 (80.0)	-1.3 (-7.3 to 4.7)	1.105	-
<b>Secondary outcome</b> - Sustained clinical response	313/475 (65.9)	322/479 (67.2)	-1,3 (-7,3 to 4,7)	1.258	-
<b>Population: clinically evaluable</b>	N =394	N =397			
<b>Primary outcome</b> - Early clinical response at the evaluation visit (48-72h) (outcome formed by stop in the spread of infection or reduction in lesion size, lack of fever and no need for antibiotic reliever medication)	344/394 (87.3)	342/397 (86.1)	1.2 (-3.6 to 5.9)	0.633	-
<b>Secondary outcome</b> - Reduction in lesion area ≥ 20 %	362/394 (9.9)	370/397 (93.2)	-1.3 (-5.0 to 2.3)	1.347	-
<b>Secondary outcome</b> - Evaluation of clinical cure by the researcher	357/394 (90.6)	352/397 (88.7)	1.9 (-2.3 to 6.2)	0.388	-
<b>Outcomes by subgroups</b>					
<b>Patients with MRSA infection in the ITT population with microbiological evaluation</b>					
<b>Primary outcome</b> - Early clinical response at the evaluation visit (48-72h) (outcome formed by stop in the spread of infection or reduction in lesion size, lack of fever and no need for antibiotic reliever medication)	84/104 (80.8)	80/100 (80.0)	0.8 (-10.1 to 11.7)	0.894	-
<b>Secondary outcome</b> - Reduction in lesion area ≥ 20 %	94/104 (90.4)	84/100 (84.0)	6.4 (-2.8 to 15.5)	0.171	-
<b>Secondary outcome</b> - Evaluation of clinical cure by the researcher	86/104 (82.7)	83/100 (83.0)	-0.3 (-10.7 to 10.0)	1.040	-
<b>Patients with MSSA infection in the ITT population with microbiological evaluation</b>					
<b>Primary outcome</b> - Early clinical response at the evaluation visit (48-72h) (outcome formed by stop in the spread of infection or reduction in lesion size, lack of fever and no need for antibiotic reliever medication)	96/116 (82.8)	92/110 (83.6)	-0.9 (-10.6 to 8.9)	1.123	-
<b>Secondary outcome</b> - Reduction in lesion area ≥ 20 %	98/116 (8.5)	94/110 (85.5)	-1.0 (-10.3 to 8.3)	1.142	-
<b>Secondary outcome</b> - Evaluation of clinical cure by the researcher	89/116 (76.7)	88/110 (80.0)	-3.3 (-14.0 to 7.4)	1.325	-

ITT: Intention to treat; MRSA: Methicillin-resistant *Staphylococcus aureus*; MSSA: Methicillin-sensitive *Staphylococcus aureus*.

to evaluate the early clinical response in the clinically assessable population. The combined "Test-of-Cure" for the population by Intent to Treat according to FDA standards included five treatments in four studies; while for the clinically assessable population it included eight treatments in seven studies. The conclusions of this network meta-analysis were that oritavancin

1200 mg was considered equivalent to vancomycin. Indirect evidence also suggests that oritavancin 1200 mg has demonstrated equivalence with linezolid (OR 1.55; CrI 95% 0.91-2.57), teicoplanin (OR 0.72; CrI 95% 0.61-1.26), tedizolid (1.51; CrI 95% 0.82-2.73) and daptomycin (OR = 2.18; 95% CrI = 0.90-5.42)<sup>24</sup>.

**Table 3.** SOLO II trial outcomes<sup>22</sup>

Variable evaluated in the study	Oritavancin N= 509	Vancomycin N= 510	Difference / ARR /HR (95% CI)	P	NNT (95% CI)
<b>Population: ITT modified</b>	N=503 (%)	N=502 (%)			
Primary outcome - Early clinical response at the evaluation visit (48-72h) (outcome formed by stop in the spread of infection or reduction in lesion size, lack of fever and no need for antibiotic reliever medication)	403/503 (80.1)	416/502 (82.9)	-2.7 (-7.5 to 2.0)	1.326	-
Secondary outcome - Reduction in lesion area ≥ 20 %	432/503 (85.9)	428/502 (85.3)	0.6 (-3.7 to 5.0)	0.799	-
Secondary outcome - Evaluation of clinical cure by the researcher	416/503 (82.7)	404/502 (80.5)	2.2 (-2.6 to 7.0)	0.375	-
Secondary outcome - Sustained clinical response	374/503 (74.4)	370/502 (73.7)	-0.6 (-4.8 to 6.1)	1.145	-
<b>Population: clinically evaluable</b>	N =427	N =408			
Primary outcome - Early clinical response at the evaluation visit (48-72h) (outcome formed by stop in the spread of infection or reduction in lesion size, lack of fever and no need for antibiotic reliever medication)	357/427 (83.6)	358/408 (87.7)	-4.1 (-8.9 to 6)	1.023	-
Secondary outcome - Reduction in lesion area ≥ 20 %	378/427 (88.5)	364/408 (89.2)	-0.7 (-5.0 to 3.6)	1.205	-
Secondary outcome - Evaluation of clinical cure by the researcher	398/427 (93.2)	387/408 (94.9)	-1.6 (-4,9 to 1,6)	1.356	-
<b>Outcomes by subgroups</b>					
<b>Patients with MRSA infection in the ITT population with microbiological evaluation</b>					
Primary outcome - Early clinical response at the evaluation visit (48-72h) (outcome formed by stop in the spread of infection or reduction in lesion size, lack of fever and no need for antibiotic reliever medication)	82/100 (82)	82/101 (81.2)	0.8 (-9.9 to 11)	0.892	-
Secondary outcome - Reduction in lesion area ≥ 20 %	96/100 (96)	91/101 (90.1)	5.9 (-1.1 to 12.9)	0.098	-
Secondary outcome - Evaluation of clinical cure by the researcher	84/100 (84)	86/101 (85.1)	-1.1 (-11.1 to 8.8)	1.145	-
<b>Patients with MSSA infection in the ITT population with microbiological evaluation</b>					
Primary outcome - Early clinical response at the evaluation visit (48-72h) (outcome formed by stop in the spread of infection or reduction in lesion size, lack of fever and no need for antibiotic reliever medication)	126/150 (84)	137/157 (87.3)	-3.3 (-11.1 to 4.6)	1.361	-
Secondary outcome - Reduction in lesion area ≥ 20 %	131/150 (87.3)	135/157 (86.0)	1.3 (-6.3 to 8.9)	0.750	-
Secondary outcome - Evaluation of clinical cure by the researcher	130/150 (86.7)	136/157 (86.6)	0 (-7.6 to 7.7)	1	-

ITT: Intention to treat; MRSA: Methicillin-resistant *Staphylococcus aureus*; MSSA: Methicillin-sensitive *Staphylococcus aureus*.

## 2. Safety

Overall, oritavancin is a well-tolerated drug, with manageable toxicity. In studies conducted until its marketing, the most common adverse effects were nausea, headache and vomiting; and the most severe, cellulitis and osteomyelitis<sup>22,23</sup>.

The safety database consisted of 3,017 patients treated with oritavancin, from 22 clinical trials, including four Phase III studies, four Phase II studies, and 14 Phase I studies. The adverse effects of interest in the SOLO trials that appeared to a higher extent in the oritavancin arm than in the

vancomycin arm included essentially infection and infestation. There were 40 cases (4%) vs. 31 (3%) respectively. These cases included 4 patients in the oritavancin arm who developed osteomyelitis (in the subsequent review, it was put forward that this could be due to the lack of efficacy of oritavancin in osteomyelitis, or failure to diagnose osteomyelitis at screening). There were a slightly higher number of cases of subcutaneous abscesses in the oritavancin arm, which represents a failure in efficacy, because the infection appeared in the site of the index infection. Cellulitis cases were balanced in both arms, which could indicate lack of efficacy, lack of the adequate

**Table 4.** Cost comparison between the treatment evaluated vs. other alternative options

Price per unit (Retail Price + VAT) <sup>a</sup>	Oritavancin 400 mg vial x 3	Vancomycin 1 g or 500 mg vials	Linezolid 600 mg infusion bags (2 mg/ml), 600 mg tablets. Powder for oral suspension	Tedizolid 200 mg vials. 200 mg tablets x 6	Tigecycline 50 mg vials.	Telcaprocin 200 mg or 400 mg vials	Daptomycin 350 mg or 500 mg vials	Dalbavancin 500 mg vial	Ceftaroline 600 mg vial
973.5 €		5.7 € (1 g)	59.6 € (vial) 35.8 € (tablet)	198.7 € (vial or tablet)	46 €	10.75 € (200 mg) 21.5 € (400 mg)	79.6 € (350 mg) 100 € (500 mg)	483.6 €	55.5 €
Cost per day	2,920.5 €	11.5 €	71.6 € (IV) 71.6 € (oral)	198.7 €	92 €	21.5 €	100 €	103.63 €	111 €
Complete treatment cost	2,920.5 €	114.5 € (10 days)	859.2 € (IV) 859.2 € (oral) (12 days <sup>b</sup> )	1,192 € (6 days <sup>b</sup> )	874 € (9.5 days <sup>b</sup> )	215 € (10 days)	1,000 € (10 days <sup>b</sup> )	1,450.8 €	1,054.5 € (9.5 days)
No. of adm.	1 adm.	20 adm.	24 adm.	6 adm.	19 adm.	12 adm.	10 adm.	2 adm.	19 adm.
Direct costs per adm. <sup>d</sup>	17.41 €	348.14 €	417.84 € (IV)	104.46 €	330.79 €	208.92 €	174.1 €	34.82 €	330.79 €
associated <sup>e</sup>	0	74.7 € (3 tests)	0	0	0	74.7 € (3 tests)	0	0	0
Global cost <sup>f</sup>	2,937.91 €	537.34 €	1,277.04 € (IV) 859.2 € (oral)	1,296.46 €	1,204.79 €	498.62 €	1,174.1 €	1,485.62 €	1,385.29 €
Incremental cost (Differential) regarding standard treatment <sup>g,h</sup>	SoC	-2,400.57 €	-1,660.87 € (IV) -2,078.71 € (oral)	-1,641.45 €	-1,733.12 €	-2,439.29 €	-1,763.81 €	-1,452.29 €	-1,552.62 €

<sup>a</sup>The price of Oritavancin in U.S.A. (1 vial = 1,033\$ = 973.5€) has been considered.

<sup>b</sup>Estimated dose of daptomycin for a patient weight of 70-80 kilos (6 mg/Kg).

<sup>c</sup>Direct costs associated: These are costs that we can consider besides the cost of the medication studied. For example, other additional medications required, monitoring and lab tests, screening tests (pharmacogenetics, biomarkers), infusion materials or management of complications. To be considered whenever relevant.

<sup>d</sup>Cost for the administration of the IV doses indicated (according to the public rates in the Community of Valencia, DOCV 5166 of 30.12.2005 updated at 24-5-2013, applying a 3% per year discount rate for its 2016 update.)  
<sup>e</sup>PKA = pharmacokinetic analysis. Cost for plasma level monitoring (according to the public rates in the Community of Valencia, DOCV 5166 of 30.12.2005 updated at 24-5-2013, applying a 3% per year discount rate for its 2016 = 24.9 € per test).

<sup>f</sup>Sum of the complete treatment cost + direct costs associated.

<sup>g</sup>Difference of global cost regarding the drug evaluated.

<sup>h</sup>The cost of hospitalization has not been considered because it is assumed to be equivalent for all treatments.

<sup>i</sup>A 14-day treatment duration is considered for the purpose of cost per day.

<sup>j</sup>A recent clinical trial (Dunne MW *et al.* Clin Infect Dis. 2015)doi: 10.1093/cid/civ982First published online: November 26, 2015) has demonstrated non-inferiority between the usual dalbavancin regimen (1000 mg IV + 500 mg IV the following week) and the 1,500 mg single dose. Given that this latter dosing regimen is not collected in the product specifications, it has not been considered in the table, but the difference in costs would be reduced by one administration, that is to say, 17.41 € less.

IM: Intramuscular; IV: intravenous; adm: administrations; TSSC: Complicated skin and soft tissue infections.

incision and drainage for infection control, or recurring infection due to underlying comorbidities.

For those subjects randomized to any of the arms, the highest incidence of drug-related adverse reactions (DRAE) which led to treatment interruption was infections and infestations (1.6% vs. 1.9% respectively). Twenty-one (21) patients (2.2%) in the oritavancin arm and 19 (1.9%) in the vancomycin arm suffered a severe adverse event (AE) which led to treatment interruption. The most common DRAEs in both the oritavancin and the vancomycin arms were nausea (17.7% and 18.3%), headache (12.6% and 11.7%), vomiting (8.2% and 8.2%), diarrhoea (6.6% and 5.7%), cellulitis (6.8% and 5.7%), constipation (6% and 6.7%), and extravasation in the infusion site (6% and 5.9%). The incidence in ALT and AST elevation, cellulitis, abscesses, subcutaneous abscesses, physical integrity of abscesses, and infection on infections and infestation, tachycardia and myalgia, were slightly higher than in patients treated with oritavancin. There were 24 subjects (4.4%) in the oritavancin arm and 11 subjects (1.9%) in the vancomycin arm in the set of SOLO trials (SOLO pool) with the adverse event of tachycardia. No specific conclusions can be drawn from this analysis. There were 27 (2.8%) and 16 (1.6%) patients with elevated ALT in the oritavancin and vancomycin arms, respectively. There were 18 (1.8%) and 16 (1.6%) patients with elevated AST in the oritavancin and vancomycin arms, respectively. Even though the history of hepatitis or liver disease (9 subjects) or the use of intravenous drugs (12 subjects) could predispose subjects to transaminase elevation, there were subjects without this past history where anomalies appeared in their liver function tests. These cases don't seem to be the result of severe sepsis or septic shock. None of the subjects met Hy's Law criteria.<sup>25</sup> There was a slightly higher incidence of severe DRAEs in diabetic subjects, with 23/138 (16.7%) in the oritavancin arm versus 18/141 (12.8%) in the vancomycin arm. However, the total number of subjects with >1 DRAE was similar in both arms. In those subjects with creatinine clearance of 30-60ml/min, 12/70 in the oritavancin arm vs. 3/54 in the vancomycin arm presented one severe adverse effect.

Within the set of patients in the SOLO I and II trials, 5 patients died (2 in the oritavancin arm and 3 in the vancomycin arm). There were 5/302 (1.7%) deaths in the SIMPLIFI study (3 in the arm with oritavancin daily dose, 2 in the arm with infrequent dosing, and none in the single-dose arm). None of the deaths seemed to be related to the research medication.

Oritavancin does not require dose adjustment in patients with mild or moderate renal or liver impairment, and it has not been researched in paediatric patients.

### 3. Economic area

There are four published pharmacoeconomic studies available; of these, three are budgetary impact studies and one is a cost-minimization study.

- The study by Wu<sup>26</sup> analyzed a theoretical model on the economic impact represented by the inclusion of oritavancin in a U.S.A. hospital for SSTI treatment. An analytical decision making model was designed, based on current clinical practice guidelines, limiting the use of oritavancin to patients with moderate-severe SSTI (Eron Classes II and III) at risk of MRSA. The model simulated a cohort of 1,000 patients with SSTI. The base case shows the mean national use of antibiotics active against MRSA (vancomycin 92%, linezolid 2%, daptomycin 6%, oritavancin 0%). In the hypothetical case, it was assumed that oritavancin will be used for 25.75% of patients (5% in hospitalized patients, 15% in ER/outpatient unit, and 80% in observation units), replacing vancomycin but not the rest of antibiotics. As a result of this change, fewer patients were treated as hospitalized, and there was an increase in the use of observation units. Direct costs were taken into account: medication, administration, monitoring, hospital stay and others. According to this model, there would be savings of 2,752 \$ per patient; most of it would be caused by a reduction in the number of hospitalizations and the use of observation units, cheaper than traditional hospitalization units.
- The study by Jensen<sup>27</sup> analyzed a theoretical model on the economic impact represented by the inclusion of oritavancin in a U.S.A. hospital for SSTI treatment, identically to the previous study<sup>43</sup>, but it evaluated two scenarios: hospital with outpatient services and without them. The results were that the use of oritavancin in 26% of patients instead of vancomycin

would represent total savings of 13% from the hospital perspective, or approximately 1,235 \$ per patient. In the model of economic impact on a hospital without outpatient services, the use of oritavancin in 26% of patients would also represent savings, though lower (9%, or approximately 634 \$ per patient).

- Another study by Wu<sup>28</sup> repeated the model of the two previous studies, but applied to a hospital in the United Kingdom. In this case, it was assumed that oritavancin would be used in 3.6% of patients; and the conclusion was that its use would represent total savings by 0.63% from the hospital perspective, or 29.23£ per patient.
- The study by Lodise<sup>29</sup> developed a cost-minimization model in order to compare the costs of patients on treatment with vancomycin while hospitalized vs. those with oritavancin administered as outpatient regimen, in patients with SSTI and few or no comorbidities (Charlson Comorbidity Index [CCI] 0 or 1). The costs associated with the use of oritavancin in the Emergency Unit (3,409.46 \$) and in the observation unit (4,220.27 \$) were lower to those for vancomycin in hospitalized patients (5,972.73-9,885.33 \$). To switch a hospitalized patient on vancomycin to outpatient treatment with oritavancin could save 1,752.46-6,475.87 \$ depending on the CCI, presence of systemic symptoms, and the use of the observation unit. If all patients hospitalized on vancomycin were treated with oritavancin at the Emergency Unit, savings per patient could be of 3,102.43 \$. Assuming that some patients could be admitted to hospital after receiving treatment with oritavancin in the Emergency Unit, it is expected that savings with oritavancin in the observation unit vs. treatment hospitalized with vancomycin will be 2,291.62 \$.

The limitations of these studies lie essentially in: a) the difficulty to extrapolate data from models based on U.S.A. data to our country, and even to Europe; b) the lower prevalence of MRSA in Europe; c) the lower impact in Spain of hospitalization and drug administration costs than in other countries; d) the risky assumption that all patients treated with oritavancin can be treated as outpatients, and those patients treated with alternative options (vancomycin, linezolid, teicoplanin, etc.) must be hospitalized.

We have conducted our own comparison of the cost of the treatment evaluated vs. those alternative options currently available in Spain (Table 4). Given that these are equivalent treatments, an incremental cost-efficacy analysis is not adequate, and a cost-minimization analysis should be conducted, considering oritavancin as a therapeutic alternative vs. the rest of drugs considered for the indication under study.

On September, 1st, 2016, oritavancin had not been yet approved by the AEMPS; therefore, its price in U.S.A. has been used for its economic evaluation: 1 vial 400 mg = 1,035 \$ = 973.5 €.

For the estimation of the overall economic impact at national level, there are no data available about the prevalence of SSTI in Spain. It is known that in U.S.A. there are 500 episodes per 10,000 persons and per year<sup>30</sup>. According to the January, 2015 census by the National Statistics Institute, there were 46.449.565 inhabitants in Spain; applying the American prevalence, this would represent a figure of 2.322.478 episodes per year. If we take the proportion of patients who required hospitalization for treatment in the SOLO I trial (19%)<sup>22</sup>, we would have 441.270 patients. For an oritavancin introduction rate of 2.5% per year (11,032 patients), on the first year we would have costs of 32,411,023€.

## Discussion

Oritavancin is a semi-synthetic derivative of chloroeremomycin, a glycopeptide antibiotic that has been approved by the FDA and the EMA for the treatment of SSTI caused by susceptible Gram-positive bacteria. This new 2<sup>nd</sup> generation lipoglycopeptide antibiotic has activity against a broad spectrum of Gram-positive bacteria, including MRSA. Its mechanism of action through three different mechanisms turns it particularly immune to microbial resistances, at least in theory. However, *in vitro* data indicate that very few *Staphylococci* that have intermediate susceptibility or are resistant to glycopeptides could be treated with oritavancin, and that there are no clinical data for the use of oritavancin when MIC > 1mg/l. It seems unlikely that it could be used to treat Intermediate Vancomycin-resistance *Staphylococcus aureus* or Vancomycin-resistance *Staphylococcus aureus*, and there are few conclusive data about its utility in hetero-VISA. Oritavancin still presents limited data regarding the development of resistance, but *in vitro* resistan-

ce has been observed in vancomycin-resistant *Staphylococcus aureus*. No cross-resistance is known between oritavancin and the non-glycopeptide antibiotic classes, and it presents reduced *in vitro* activity against certain Gram-positive organisms of the *Lactobacillus*, *Leuconostoc* and *Pediococcus* classes, which are intrinsically resistant to glycopeptides<sup>17</sup>.

From a clinical point of view, oritavancin as single-dose has demonstrated its non-inferiority in controlled studies vs. vancomycin in skin and soft tissue infection, with a safety profile similar to the comparator. Due to its lower development, there is limited experience in clinical trials with patients with bacteremia, peripheral vascular disease, those under immunosuppression, >65-year-old, and in infections caused by *S. pyogenes*. Its safety has not been established in pregnant women or the paediatric population.

Oritavancin is incorporated into a well-provided therapeutic class, where it is difficult to find any gaps. Its potential advantage over other treatment alternative options available would be based on its single administration and lack of monitoring required for plasma levels, which at least in theory makes its outpatient administration possible, reducing direct treatment costs, shortening the duration of hospital stay, and indirectly minimizing the risk of nosocomial complications. Regarding the alternative options for oral treatment (linezolid, tedizolid), it would eliminate the likelihood of lack of treatment compliance.

However, its longer duration of action could represent a safety problem in case of reactions due to lack of tolerability or hypersensitivity. The long elimination half-life also causes concern about the development of resistance, particularly when the drug concentration falls below the MIC for the pathogen causing the infection. On the other hand, it is expected that the multiple mechanisms of action of oritavancin will protect against the development of resistance during treatment.

Finally, given its prolonged half-life, its "off-label" use must be foreseen in specific situations such as, for example, completing the osteomyelitis treatment and other osteoarticular infections.

In terms of economic evaluation, even though so far there is no official price available for oritavancin in Spain, we know its price in U.S.A. (973.5 €). This cost is overall much higher than the one for the rest of antibio-

tics it is compared with (vancomycin, linezolid, teicoplanin, tedizolid, etc.), and it has the advantage over them of its single-dose. This aspect could lead to higher efficiency in specific scenarios (outpatient treatment with oritavancin vs. hospital treatment with the alternative options), but so far there are no compelling or sufficiently detailed studies in this sense. On the other hand, some alternative drugs (linezolid, tedizolid or teicoplanin) can also allow outpatient treatment (oral or IM), at some point in the clinical process; this would reduce the advantages of oritavancin and would increase even more the differences in cost.

## Therapeutic positioning and conditions of use

Given that, in the indications evaluated, the medication shows efficacy and safety comparable to the alternative options available, and its efficiency profile does not offer improvements in the cost-effectiveness ratio, the proposed positioning is to consider it within the Category D-1: Included in the Formulary with specific recommendations: treatment of infection by vancomycin-resistant enterococcus in adult patients, when there is contraindication to the use of linezolid or tedizolid.

## Funding

No funding

## Acknowledgments

The authors would like to thank Dr. Javier Cobo Reinoso, of the Infectious Diseases Service of the Hospital Ramón y Cajal (Madrid, Spain) and member of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), for his valuable contributions, which have contributed to the improvement of the document.

## Conflict of interests

No conflict of interest.

## Bibliography

1. FDA Guideline ABSSSI 2013 [Internet]. [Consultado diciembre 2015]. Disponible en: <http://www.fda.gov/downloads/Drugs/.../Guidances/ucm071185.pdf>
2. EMA Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections [Internet]. [Consultado diciembre 2015]. Disponible en: [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/Scientific\\_guideline/2009/09/WC500003417.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003417.pdf)
3. EMA Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections [Internet]. [Consultado diciembre 2015]. Disponible en: [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/Scientific\\_guideline/2013/11/WC500153953.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/11/WC500153953.pdf)
4. Cardona AF, Wilson SE. Skin and soft-tissue infections: a critical review and the role of telavancin in their treatment. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2015;61(Supl. 2): S69–78.
5. Edelsberg J, Taneja C, Zervos M, Haque N, Moore C, Reyes K, et al. Trends in US Hospital Admissions for Skin and Soft Tissue Infections. *Emerg Infect Dis*. 2009;15(9):1516–8.
6. Lima ALLM. Parte II – Infecciones de tejidos blandos: Epidemiología y clasificación. *Rev Panam Infectol*. 2013;15(Supl. 1):S39-41 [Internet]. [Consultado diciembre 2015]. Disponible en: <http://www.revistaapi.com/artigo/epidemiologia-y-clasificacion/>
7. Llopis F, González-Castillo J, Julián-Jiménez A, Ferré C, Gamazo-Río JJ, Martínez M, et al. Review of 1.250 episodes of skin and soft tissue infections attended at 49 hospital emergency departments. *Rev Esp Quimioter Publ Of Soc Esp Quimioter*. 2014;27(2):115–21.
8. Montejo Baranda M, Oñate Adrián J, Basterretxea Ozamiz A. Organización y tratamiento de la infección de piel y partes blandas. *Protocolos de actuación 2013. Hospital de Cruces (Osakidetza)* [Internet]. [Consultado diciembre 2015]. Disponible en: [http://www.hospitalcruces.com/documentos/protocolosHospitalarios/Infecci%C3%B3nPielPartesBlandas\\_mayo\\_2013\(1\).pdf](http://www.hospitalcruces.com/documentos/protocolosHospitalarios/Infecci%C3%B3nPielPartesBlandas_mayo_2013(1).pdf)
9. Sartelli M, Malangoni MA, May AK, Viale P, Kao LS, Catena F, et al. World Society of Emergency Surgery (WSES) guidelines for management of skin and soft tissue infections. *World J Emerg Surg*. 2014;18(9):57.
10. Porras Leal L, Sáenz Gutiérrez A, Calderón Jiménez P, Gijón Rodríguez J. *Protocolos SEMI infección de piel y partes blandas capítulo 5, 2009* [Internet]. [Consultado diciembre 2015]. Disponible en: [https://www.fesemi.org/sites/default/files/documentos/publicaciones/capitulo-5\\_5.pdf](https://www.fesemi.org/sites/default/files/documentos/publicaciones/capitulo-5_5.pdf)
11. Garau J, Ostermann H, Medina J, Avila M, McBride K, Blasi F, et al. Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010-2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study. *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis*. 2013;19(9):E377–85.
12. Salgado Ordóñez F, Arroyo Nieto A, Lozano Serrano AB, Hidalgo Conde A, Verdugo Carballada J. Infecciones de piel y partes blandas. *Med Clínica*. 2009;133(14):552–64.
13. Currie CJ, Berni E, Jenkins-Jones S, Poole CD, Ouwens M, Driessen S, et al. Antibiotic treatment failure in four common infections in UK primary care 1991-2012: longitudinal analysis. *BMJ*. 2014; 23;349:g5493.
14. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2014. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC. [Consultado 2015]. Disponible en: <http://ecdc.europa.eu/en/publications/publications/antimicrobial-resistance-europe-2014.pdf>
15. European Medicines Agency. Orbactiv®. Assessment report. [Consultado diciembre 2015]. Disponible en: [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_-\\_Public\\_assessment\\_report/human/003785/WC500186347.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003785/WC500186347.pdf)
16. FDA Center For Drug Evaluation And Research- Clinical Review Orbactiv (NDA 206334). [Consultado diciembre 2015]. Disponible en: [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2014/206334Orig1s000MedR.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206334Orig1s000MedR.pdf)
17. European Medicines Agency. Orbactiv®. Summary of product characteristics [Internet]. [Consultado diciembre 2015]. Disponible en: [http://www.ema.europa.eu/docs/es\\_ES/document\\_library/EPAR\\_-\\_Product\\_Information/human/003785/WC500186343.pdf](http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/003785/WC500186343.pdf)
18. Zhanel GG, Schweizer F, Karlowsky JA. Oritavancin: Mechanism of Action. *Clin Infect Dis*. 2012; 15;54(Supl. 3):S214–9.



19. Marín R, Puigventós F, Fraga MD, Ortega A, López-Briz E, Arocas V, *et al.* Group for Innovation, Assessment, Standardisation and Research in the Selection of Drugs (GENESIS) of the Spanish Society of Hospital Pharmacy (SEFH). Support method for decision making in assessment and appraisal of medicines (MADRE). Version 4.0. Madrid: SEFH (ed.); 2013. [Consultado diciembre 2015]. Disponible en: [http://gruposdetrabajo.sefh.es/genesis/genesis/Documents/MADRE%204\\_0\\_Procedures%20manual\\_Dec\\_2013.pdf](http://gruposdetrabajo.sefh.es/genesis/genesis/Documents/MADRE%204_0_Procedures%20manual_Dec_2013.pdf)
20. Ortega Eslava A, Marín Gil R, Fraga Fuentes MD, López-Briz E, Puigventós Latorre F (GENESIS-SEFH). Guía de evaluación económica e impacto presupuestario en los informes de evaluación de medicamentos. Guía práctica asociada al programa MADRE v 4.0. [Internet]. SEFH. Madrid; 2016 [Consultado 20/03/2017]. Disponible en: [http://gruposdetrabajo.sefh.es/genesis/genesis/Documents/GUIA\\_EE\\_IP\\_GENESIS-SEFH\\_19\\_01\\_2017.pdf](http://gruposdetrabajo.sefh.es/genesis/genesis/Documents/GUIA_EE_IP_GENESIS-SEFH_19_01_2017.pdf)
21. Dunbar LM, Milata J, McClure T, Wasilewski MM, SIMPLIFI Study Team. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. *Antimicrob Agents Chemother.* 2011;55(7):3476–84.
22. Corey GR, Kabler H, Mehra P, Gupta S, Overcash JS, Porwal A, *et al.* Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections. *N Engl J Med.* 2014;370(23):2180–90.
23. Corey GR, Good S, Jiang H, Moeck G, Wikler M, Green S, *et al.* Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. *Clin Infect Dis Off Publ Infect Dis Soc Am.* 2015;60(2):254–62.
24. Thom H, Thompson JC, Scott DA, Halfpenny N, Sulham K, Corey GR. Comparative efficacy of antibiotics for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a systematic review and network meta-analysis. *Curr Med Res Opin.* 2015;31(8):1539–51.
25. Björnsson E. Drug-induced liver injury: Hy's rule revisited. *Clin Pharmacol Ther.* 2006;79(6):521–8.
26. C. Wu KJF. A US Hospital Economic Impact Model for Oritavancin In ABSSSI Patients With Risk of MRSA Infections. *Value Health.* 2014;17(7):A605.
27. Jensen IS, Lodise TP, Fan W, Wu C, Cyr PL, Nicolau DP, *et al.* Use of Oritavancin in Acute Bacterial Skin and Skin Structure Infections Patients Receiving Intravenous Antibiotics: A US Hospital Budget Impact Analysis. *Clin Drug Investig.* 2016;36(2):157-68.
28. Wu C, Jensen IS, Cyr PL, Fan W, Mitchell M, Sulham K, *et al.* Use of Oritavancin for the Treatment of Skin and soft Tissue Infections: A UK Hospital Budget Impact Analysis. *Value Health.* 2015;18(3):A233.
29. Lodise TP, Fan W, Sulham KA. Economic Impact of Oritavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in the Emergency Department or Observation Setting: Cost Savings Associated with Avoidable Hospitalizations. *Clin Ther.* [Internet]. [Consultado 13/01/2016]. Disponible en: <http://www.clinicaltherapeutics.com/article/S0149291815012989/abstract>
30. Ray GT, Suaya JA, Baxter R. Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a U.S. population: a retrospective population-based study. *BMC Infect Dis.* 2013;30(13):252.